



Outpatient treatment with the wearable cardioverter defibrillator:
clinical experience in two Dutch centres
A. F. B. E. Quast1 · V. F. van Dijk2 · A. A. M. Wilde1 · R. E. Knops1 · L. V. A. Boersma2
© The Author(s) 2017. This article is available at SpringerLink with Open Access.
Abstract
Introduction The latest European Society of Cardiology
Guidelines recommend consideration of a wearable car-
dioverter-defibrillator (WCD) for patients with a poor left
ventricular ejection fraction (LVEF) who are at risk of sud-
den arrhythmic death but are not eligible for an implantable
defibrillator. For these patients a WCD can be an alternative
to long-term hospitalisation.
Purpose To evaluate the use of WCD therapy in these
patient groups in two Dutch centres.
Methods All consecutive patients treated with the WCD
between 2009 and 2016 were included from two centres
in the Netherlands. Data on events and compliance were
collected retrospectively through home monitoring systems
and adjudicated by the investigators.
Results A total of 79 patients were treated with a WCD.
Common indications were newly diagnosed cardiomy-
opathy without optimal medical treatment in 46 patients
(58.2%) and bridge to implantable cardioverter-defibrillator
(ICD) implant in 33 patients (41.8%). Bridge to implant
indications consisted of contraindications for immediate
implantation such as infections (e. g. previous device-re-
lated infections) and radiotherapy. Compliance was over
97% per day (median 23.3 h, 22.6–23.7), during a median
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of 79 days (50.0–109.8.0). Two patients (2.6%) received an
appropriate shock (annual rate 13.6%), there was 1 (1.3%)
inappropriate shock (annual rate 6.7%). In 24 patients
(52.2%) without optimal medical treatment, the LVEF was
sufficiently improved and ICD implant was avoided. Eight
(10.1%) patients did not receive an ICD. In 45 patients an
ICD was implanted (57.0%).
Conclusion WCD therapy provides a safe and effective
treatment in outpatient setting for patients at high risk for
sudden cardiac death and reduces the number of ICDs im-
planted.
Keywords Wearable cardioverter defibrillator · Sudden
death · Ventricular arrhythmias
Introduction
An implantable cardioverter-defibrillator (ICD) is indicated
in patients at risk for sudden cardiac death (SCD) due to
ventricular arrhythmias, especially in patients with a re-
duced left ventricular ejection fraction (LVEF) [1]. Before
an ICD indication can be established in patients with a de
novo reduced LVEF, more than three months of optimal
medical treatment (OMT) is required to allow improvement
of the LVEF [2]. A time delay (of 40 days) is also pertinent
for patients with recent myocardial infarction and/or revas-
cularisation [3, 4]. The latest European Society of Cardi-
ology (ESC) guidelines recommend class 2b consideration
of the wearable cardioverter-defibrillator (WCD) in patients
with a poor left ventricular (LV) function who are at risk
of sudden arrhythmic death for a limited period, but are
not candidates for an ICD [1]. Incidence of improvement
of LVEF in newly diagnosed ischaemic and non-ischaemic
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cardiomyopathies is up to 41% [5]. Use of the WCD may
therefore prevent non-evidence-based ICD implantations.
With a rapidly increasing population of ICD patients, the
prevalence of ICD-related infections is increasing as well.
In most cases, extraction of the device and leads is neces-
sary. Recommendations of the Heart Rhythm Society state
that the WCD can be an alternative to early re-implanta-
tion of an ICD when there is concern for ongoing infection
[6]. Other indications for bridging to implant can be a cur-
rent infection elsewhere, need for radiotherapy in the area
of the ICD and a suspected arrhythmia disorder in which
evaluation is still ongoing.
Continuous rhythm monitoring is provided by the WCD
as well as detection of possibly fatal arrhythmias and auto-
matic defibrillation of these arrhythmia episodes. Without
the WCD these patients are bound to long-term hospitali-
sation for continuous rhythm monitoring to avoid SCD.
The effectiveness of the WCD was first described in
1998 [7]. Afterwards several large registries have proven
the WCD to be a safe and effective treatment of episodes
of potentially fatal arrhythmias [5, 8, 9]. The first use of
the WCD in the Netherlands was described in 2011 [10].
A recent publication shows that WCD use in Europe is re-
stricted and depends mainly on reimbursement [11]. The
current study aims to describe the current use, number of
prevented ICD implants and costs of WCD therapy in the
Netherlands.
Methods
All consecutive patients, from two large tertiary heart cen-
tres, who were treated with the WCD (Life Vest, ZOLL,
Pittsburgh, PA) between 2009 and 2016, were included.
Data on baseline characteristics, indication, duration of
WCD wear and compliance, WCD therapy and adverse
events were retrospectively collected through home moni-
toring systems and patient files.
Recorded episodes of arrhythmias were adjudicated by at
least two investigators. Aborted therapy was defined as a de-
tected episode for which the WCD was preparing to give
therapy before this was manually aborted by the patient.
Continuous variables are expressed as median, interquartile
range (IQR) or mean ± standard deviation, depending on
the distribution of the parameter.
For cost estimation, referential prices calculated by the
Dutch Health Care Institute were used [12]. Specific costs
for the cardiac outpatient follow-up visits were provided by




Between 2009 and 2016, 79 patients were treated with the
WCD. All patients received their WCD within 24 h after
the WCD indication was established and no other indica-
tion for hospitalisation remained. No patients were lost to
follow-up; 61 patients were male (87.5%), median age was
54.0 (IQR 43.8–64.3) and the median baseline LVEF was
25% (IQR 18.0–39.3%). Seven patients (8.6%) were diag-
nosed with a genetic arrhythmia, 42 patients (51.9%) with
non-ischaemic cardiomyopathy and 30 patients (37%) with
ischaemic cardiomyopathy. One patient was suspected of
Wolff-Parkinson-White syndrome and wore a WCD until
definite diagnosis and ablation. One patient had non-sus-
tained ventricular tachycardia (VT) and was suspected of
cardiac involvement of myositis and 1 patient had VT orig-
inating in the area of an apical aneurysm after atrial septum
defect closure (Table 1).
The most common indication for WCD therapy was
newly diagnosed cardiomyopathy, either ischaemic or non-
ischaemic (46 patients, 58.2%). These patients were con-
sidered to be at high risk of ventricular arrhythmias, in most
cases due to repetitive non-sustained VT or primary ven-
tricular fibrillation (VF) at the time of myocardial infarction
and a severely reduced LVEF. A total of 33 patients received
WCD therapy as a bridge to ICD implant. Device-related
infection occurred in 24 patients, 4 patients had an infection
elsewhere, 2 patients had their ICD extracted in order to re-
ceive radiotherapy treatment, 2 patients needed to undergo
cardiac surgery before implantation and 1 patient chose to
wear a WCD while deciding if he wanted to proceed with
ICD implantation after an episode of idiopathic VF.
Ventricular arrhythmias had been documented in 58 pa-
tients (73.4%), mostly non-sustained VT in 32 patients,
sustained VT in 16 patients (27.6%) and VF in 10 pa-
tients (17.2%). Cardiac electronic implantable devices were
previously implanted in 26 patients (32.9%), of which 8
transvenous ICDs, 6 subcutaneous ICDs (S-ICD), 1 pace-
maker and 11 cardiac resynchronisation therapy-defibrilla-
tors (CRT-D). Of these 26 patients, 23 suffered a device-
related infection, and all devices were extracted (Table 1).
Two patients had an indication for device extraction due to
radiation therapy, in 1 patient with a pacemaker the system
was upgraded to an ICD.
WCD compliance and therapy
Compliance was over 97% a day (median 23.3 h, IQR
22.6–23.7), during a median treatment duration of 79 days
(IQR 50.0–109.8). Patients wearing the WCD as a bridge
to implant used the device for a median of 79.0 days
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Table 1 Baseline characteristics
Characteristic Patients (n = 79)
Male (n, %) 59 (74.9%)
Age, years (median, IQR) 54.0 (43.8–64.3)










Ischaemic CMP (n, %) 29 (36.7%)
































Indication WCD (n, %)
Newly diagnosed iCMP
Newly diagnosed non-iCMP
Bridging to implant due to infection
























LVEF, % (median, IRQ) 25.0 (18.0–39.3)
AV(N)RT atrioventricular (nodal) re-entry tachycardia, CIED cardio
implantable electronic device, CMP cardiomyopathy, iCMP ischaemic
CMP, non-iCMP non-ischaemic CMP, DPP6 dipeptidylpeptidase 6,
HCM hypertrophic cardiomyopathy, IQR interquartile range,
LQTS long-QT syndrome, LVEF left ventricular ejection fraction,
S-ICD subcutaneous implantable cardioverter-defibrillator,
TV-ICD transvenous implantable cardioverter-defibrillator,
WCD wearable cardioverter-defibrillator
(IQR 54.8–102.3). In the patients with newly diagnosed
cardiomyopathy this was 82.0 days (IQR 44.0–92.0).
Two patients (2.6%) received appropriate and successful
therapy (calculated annual rate 13.6%) (Table 2). In 1 pa-
tient, the initial shock was successful. In the other patient
a second shock was required to restore sinus rhythm. Both
patients were previously treated with an ICD because of
ischaemic cardiomyopathy.
One patient (1.3%), diagnosed with ischaemic cardiomy-
opathy, experienced an inappropriate shock (calculated an-
nual rate 6.7%). The mechanism was oversensing due to
noise while putting on the vest. No malfunctioning of the
device was observed; however, the patient received a new
Lifevest. The patient experienced no disability after the in-
appropriate shock.
The home monitoring system recorded at least 1 episode
of manually aborted therapy in 48 patients. Most cases were
inappropriate sensing due to noise.
ICD implantations
Of the 46 patients with a newly diagnosed cardiomyopathy,
24 (52.1%) had a sufficiently improved LVEF, therefore
ICD implantation was not indicated at the time of final
evaluation. Four of them had ischaemic cardiomyopathy
with successful revascularisation (16.6%), and 19 had de
novo non-ischaemic cardiomyopathy (79.2%). One patient
(4.2%) used the WCD as bridge to implant. This last pa-
tient was not equipped with a permanent ICD because of an
infection but had an improved LVEF at the end of the treat-
ment for the infection (Table 2). One patient did not have
an ICD indication after successful ablation of a malignant
accessory bundle. Eight patients (10.1%) did not receive an
ICD despite a clear indication. Three of them refused ICD
implantation; 1 received a left ventricular assist device, and
4 patients died before planned ICD implantation (not due to
arrhythmia). In 45 patients an ICD was implanted (57.0%)
(Table 2).
Mortality
Five patients (6%) died during treatment with the WCD.
However, no arrhythmic deaths were observed. Two patients
died of end-stage heart failure, the others from pneumo-
nia, malignancy and type A dissection, respectively. In the
24 patients with improved LVEF during the use of WCD,
who therefore did not receive an ICD, no ventricular ar-
rhythmia or SCD was reported after cessation of WCD ther-
apy, during a median follow-up of 1.6 years (IQR 0.1–3.3).
Of the 3 patients who had refused ICD implantation despite
a clear indication following current guidelines, 1 patient
died at home from SCD.
Costs
Costs for the use of the WCD in the Netherlands are 3000 C,
charged per calendar month. After patients are discharged
they are seen after a few days for a routine check-up. Fur-
ther follow-up is done through home monitoring. Included
in the calculated costs as presented in Table 3 are: WCD
hire, check-up by pacemaker/ICD technician in outpatient
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Table 2 Results Results Patients (n = 79)
LVEF end WCD wear, % (median, IQR) 37.5 (23.5–45.8)
Number of days WCD wear (median, IQR) 79.0 (50.0–109.8)
Average hours WCD wear a day (median, IQR) 23.3 (22.6–23.7)
Appropriate therapy (n, %) 2 (2.6%)
Inappropriate therapy (n, %) 1 (1.3%)











Patients with recovered LVEF after WCD (n, %) 24 (30.4%)
Patients with ICD indication that were not implanted (n, %)
Patient refused ICD
Patient deceased before implantation





Hospitalisation days prevented in ‘bridge-to-implantation’ patients (median, IQR) 79.0 (54.8–102.3)
IQR interquartile range, LVEF left ventricular ejection fraction, S-ICD subcutaneous implantable cardiovert-
er-defibrillator, TV-ICD transvenous implantable cardioverter-defibrillator, WCD wearable cardioverter-de-
fibrillator
Table 3 Calculated estimation
of costs of WCD wear compared
with hospitalisation as bridge to
implant for several time periods
WCD in C Hospitalisation in C Difference in C
2 weeks 3993 6664 2671
4 weeks 3993 12,796 8.803
6 weeks 6993 19,194 12,201
8 weeks 6993 26,656 19,663
10 weeks 9993 33,320 23,327
12 weeks 9993 39,984 29,991
WCD wearable cardioverter-defibrillator
clinic (41 C/visit) and 1 extra day of hospital admission
during which the patient is instructed how to use the WCD
(476 C/day). Costs of hospitalisation are calculated by us-
ing the average cost per day in a Dutch hospital on a nursing
ward as calculated by the Dutch Health Care Institute. No
additional costs were added in the calculation of costs for
hospitalisation. The difference in calculated costs in favour
of WCD ranges from 2671 to 23,327 C depending on du-
ration of treatment (Table 3).
Discussion
This study describes the largest Dutch cohort of WCD pa-
tients to date. Results show that for various indications,
the WCD is a safe and effective treatment for ambulant
monitoring and treatment of patients at risk of ventricular
arrhythmia.
Population
All patients in this cohort meet the specified criteria for
which the latest ESC guidelines recommend WCD therapy.
These results can therefore be considered representative for
the population that is eligible for a WCD [1]. Compared
with other WCD registries, baseline characteristics are sim-
ilar [5, 9].
The utility of the WCD in patients with newly diag-
nosed non-ischaemic cardiomyopathy has been questioned
by Singh et al. [13]. They concluded that the risk of appro-
priate therapy, and therefore SCD, in this particular sub-
population is minimal. On the other hand, specific patients
could be classified as having a relatively high risk of ven-
tricular arrhythmia, for example in patients with recurrent
non-sustained VT or patients with incomplete revasculari-
sation.
WCD compliance and therapy
Patient compliance is excellent with a median wearing time
of more than 23 h a day, which in addition to instruction
and management is crucial for optimal protection. Median
WCD wear in patients bridging to ICD implant in case of
device-related infection in this cohort is longer than the pe-
riod of treatment recommended by current guidelines. This
can be explained by the fact that these patients are not hospi-
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talised, therefore there is no need for minimal recovery time
to re-implantation to reduce the period of hospitalisation.
Outpatient therapy is cost-effective and gives a lower risk of
hospital-acquired complications compared with long-term
hospitalisation. Furthermore, it is associated with greater
quality of life compared with inpatient treatment [14, 15].
No arrhythmic deaths were observed in this population,
and all episodes of VT/VF were effectively treated by the
WCD with an annual shock rate of 13.6%. As compared
with the presented data, Singh reported a comparable inci-
dence (1 shock per 7.8 patient-years). In the Wearit II trial,
this was somewhat lower (5%). In a large cohort of post
myocardial infarction patients treated with the WCD, the
annual shock rate was calculated at 8.4% [16]. This com-
parison implies that the patients in the current trial are com-
parable with other WCD data and are truly at an elevated
risk of ventricular arrhythmia.
One patient received an inappropriate shock due to
noise oversensing. Noise oversensing is very common in
the WCD, as can be seen by the large percentage of patients
in which aborted therapy occurred (63.2%). The algorithms
to prevent inappropriate shock together with the option
to deactivate the device manually make the inappropriate
shock rate low. Adequate patient instruction is crucial, as
patients have to be able to prevent inappropriate therapy by
deactivating the device manually. This might be considered
a limitation of the device, as good instruction is mandatory
and patients who are not willing or able to follow all the
instructions should be precluded from WCD therapy.
ICD implants
More than half of the 46 patients (52.1%) with a WCD as
bridge to possible recovery in this cohort had a sufficiently
improved LVEF (>35%) at time of final evaluation. This
finding is in line with other registries [5, 8, 13] and supports
the use of the WCD in obtaining a more accurate prophy-
lactic ICD indication, with adequate protection in the early
phase after diagnosis for specific patients who could be at
specifically high risk of ventricular arrhythmia. This is ex-
pected to decrease the number of non-evidence-based ICD
implants. Data from the United States showed that 22.5%
of ICD implantations did not meet evidence-based criteria
for implantation [17]. Most of these were implanted within
40 days of myocardial infarction, within three months of
coronary artery bypass grafting or newly diagnosed heart
failure without OMT [17].
Costs
When considering WCD therapy, costs are of particular
interest. In the Netherlands there is no well-defined re-
imbursement for this therapy. As mentioned before, WCD
therapy is directly dependent on reimbursement [11]. Less
than half of the responding centres in this survey confirmed
the use of the WCD. Furthermore, 48% of these centres
responded to have only used the WCD in <10 patients in
the past year [11]. Costs can therefore be considered the
major obstacle for physicians in using WCD therapy. Cost
estimation in this study is meant to provide further insight
into estimated costs of both treatment strategies.
WCD therapy could be perceived to be an expensive
form of outpatient ICD treatment. However, our data show
that during 12 weeks of use up to 30,000 C might actually
be saved by using the WCD (Table 3). Nonetheless, there
are important limitations to this calculation. Numerous fac-
tors are included in a complete cost calculation. Patients
can suffer complications of either treatment and therefore
require additional hospitalisation, emergency room visits,
ambulance transportation or additional treatment. In addi-
tion to that, ICD re-implantation might be scheduled on
a shorter term in a clinical setting than in case of outpa-
tient treatment, but our estimation implies that there is an
incremental gain in costs with longer treatment, in favour
of the WCD. Cost-effectiveness of the WCD as a bridge
to implant has previously been established by Healy et al.
for patients with an infected cardioverter-defibrillator in the
United States [18].
In patients with a newly diagnosed cardiomyopathy who
are considered at high risk of SCD, bridging to recovery
saves the costs of a possible non-evidenced based ICD im-
plantation and lifetime follow-up, in case of recovery (in
52.1% in this study). On top of financial impact, the disad-
vantages of ICD therapy can be avoided in patients that do
not meet evidence-based criteria.
Conclusion
The WCD is a safe and effective treatment in an outpa-
tient setting in patients in whom the indication for ICD is
yet to be determined or device implantation is temporarily
contraindicated. In patients with a newly diagnosed car-
diomyopathy the number of non-evidence-based ICD im-
plantations can be reduced with use of the WCD, as well as
morbidity and reduction of quality of life due to long-term
hospitalisation in patients with a bridge to implantation in-
dication.
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